Based on the aggregated intelligence of 135,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, genetic analysis company Illumina (NASDAQ:ILMN) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Illumina's business, and see what CAPS investors are saying about the stock right now.

Illumina facts

Headquarters (founded)

San Diego (1998)

Market Cap

$4.76 billion


Life Sciences Tools and Services

TTM Revenue

$617.1 million


CEO Jay Flatley (since 1999)
CFO Christian Henry (since 2005)

Compound Annual Revenue Growth (over last five years)



Affymetrix (NASDAQ:AFFX)
Life Technologies

CAPS members bullish on ILMN also bullish on

Johnson & Johnson (NYSE:JNJ)
Marvel (NYSE:MVL)

CAPS members bearish on ILMN also bearish on

Research In Motion (NASDAQ:RIMM)
First Solar (NASDAQ:FSLR)

Sources: Capital IQ, a division of Standard & Poor's, and Motley Fool CAPS. TTM = trailing 12 months.

Over on CAPS, fully 500 of the 545 members who have rated Illumina -- some 92% -- believe the stock will outperform the S&P 500 going forward. These bulls include Ybean and All-Star Gumfactor, who is ranked in the top 5% of our community.

Late last year, Ybean noted that Illumina "is the current market leader in DNA sequencing and SNP [single nucleotide polymorphism] detection." Our CAPS member concludes: "As more and more Universities and Institutes start buying its products, Illumina's revenue will continue its exponential growth for the next few years."

In a more recent pitch from April, Gumfactor illuminates on Illumina's healthy stimulant:

I work in neuroscience/genetic research. And let me tell you -- the whole scientific community is dancing in the streets over the stimulus funds that were given to NIH [National Institutes of Health]. Currently NIH is offering grants of up to $2 million that are dedicated to equipment and infrastructure. Which means that over the next two years, companies that make biological/genetic/laboratory equipment are going to be showing exorbitant growth. I don't know about long-term perspectives on any of these companies, but for the next two years, they're gold.

What do you think about Illumina, or any other stock for that matter? Make your voice heard on Motley Fool CAPS today. More than 135,000 investors are waiting to hear what you have to say. CAPS is 100% free, so simply click here to get started.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Illumina, Apple, and Marvel are Motley Fool Stock Advisor picks. Johnson & Johnson is an Income Investor pick. The Fool's disclosure policy always gets a perfect score.